Clinical progress of leucine-rich glioma inactivated-1 antibody-mediated encephalitis
10.3760/cma.j.issn.1671-8925.2019.03.019
- VernacularTitle:富亮氨酸胶质瘤失活1蛋白抗体相关脑炎的临床进展
- Author:
Xiao LIU
1
;
Wei SHAN
;
Jiechuan REN
;
Guoping REN
;
Qun WANG
Author Information
1. 首都医科大学附属北京天坛医院神经病学中心
- Keywords:
Leucine-rich glioma inactivated-1;
Faciobrachial dystonic seizure;
Hyponatremia;
Positron emission tomography;
Immunotherapy
- From:
Chinese Journal of Neuromedicine
2019;18(3):306-311
- CountryChina
- Language:Chinese
-
Abstract:
Leucine-rich glioma inactivated-1 (LGI-1) antibody-mediated encephalitis is a subtype of autoimmune encephalopathy associated with antibody against neuronal plasma membrane proteins ADAM23 binding protein LGI-1. The main symptoms of this disease are characterized by seizures, faciobrachial dystonic seizures, cognitive deficits, neuropsychiatric disturbances, and intractable hyponatremia. The disease diagnosis mainly depends on positive expression of LGI1 antibody in serum or cerebrospinal fluid. Early diagnosis combined with immunotherapy can apparently improve prognosis and reduce the risk of disease recurrence. However, due to the delayed diagnosis or misdiagnosis, the patients always result in poor prognosis. The objective of this review is to raise awareness of LGI-1 antibody encephalitis. Thus, in this study, we summarize the etiology, pathogenesis, clinical presentations, imaging, diagnosis, treatments and prognoses of this disease based on the latest research progress to improve the diagnosis and curative effect.
